Myofibroblasts are responsible for wound closure that occurs in healed acute wounds. However, their actions can result in disfiguring scar contractures, compromised organ function, and a tumor promoting stroma. Understanding the mechanisms regulating their contractile machinery, gene expression, and lifespan is essential to develop new therapies to control their function.
Recent Advances:
Mechanical stress and transforming growth factor beta-1 (TGF-β1) regulate myofibroblast differentiation from mesenchymal progenitors. As these precursor cells differentiate, they assemble a contractile apparatus to generate the force used to contract wounds. The mechanisms by which mechanical stress promote expression of contractile genes through the TGF-β1 and serum response factor pathways and offer therapeutic targets to limit myofibroblast function are being elucidated.
Critical Issues:
Emerging evidence suggests that the integration of mechanical cues with intracellular signaling pathways is critical to myofibroblast function via its effects on gene expression, cellular contraction, and paracrine signaling with neighboring cells. In addition, while apoptosis is clearly one pathway that can limit myofibroblast lifespan, recent data suggest that pathogenic myofibroblasts can become senescent and adopt a more beneficial phenotype, or may revert to a quiescent state, thereby limiting their function.
Future Directions:
Given the important role that myofibroblasts play in pathologies as disparate as cutaneous scarring, organ fibrosis, and tumor progression, knowledge gained in the areas of intracellular signaling networks, mechanical signal transduction, extracellular matrix biology, and cell fate will support efforts to develop new therapies with a wide impact.
Get full access to this article
View all access options for this article.
References
1.
WynnTA, RamalingamTR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med, 2012; 18:1028.
2.
TomasekJJ, GabbianiG, HinzB, ChaponnierC, BrownRA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol, 2002; 3:349.
3.
DarbyI, SkalliO, GabbianiG. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest, 1990; 63:21.
4.
DuginaV, FontaoL, ChaponnierC, VasilievJ, GabbianiG. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci, 2001; 114:3285.
VedrenneN, CoulombB, DanigoA, BontéF, DesmoulièreA. The complex dialogue between (myo)fibroblasts and the extracellular matrix during skin repair processes and ageing. Pathol Biol, 2012; 60:20.
7.
DulauroyS, Di CarloSE, LangaF, EberlG, PedutoL. Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med, 2012; 18:1262.
8.
QuanTE, CowperSE, BucalaR. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep, 2006; 8:145.
9.
KalluriR, NeilsonEG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest, 2003; 112:1776.
10.
GlasserSR, JulianJ. Intermediate filament protein as a marker of uterine stromal cell decidualization. Biol Reprod, 1986; 35:463.
11.
Toccanier-PelteM-F, SkalliO, KapanciY, GabbianiG. Characterization of stromal cells with myoid features in lymph nodes and spleen in normal and pathological conditions. Am J Pathol, 1987; 129:109.
12.
SappinoAP, DietrichPY, SkalliO, WidgrenS, GabbianiG. Colonic pericryptal fibroblasts. Differentiation pattern in embryonic and phenotypie modulation in epithelial proliferative lesions. Virchows Arch A Pathol Anat Histopathol, 1989; 415:551.
13.
KayeGI, LaneN, PascalPR. Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. II. Fine structure aspects of normal rabbit and human colon. Gastroenterology, 1968; 54:852.
14.
SkalliO, RoprazP, TrzeciakA, BenzonanaG, GillessenD, GabbianiG. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol, 1986; 103:2787.
15.
CzernobilskyB, ShezenE, Lifschitz-MercerB, FogelM, LuzonA, JacobN, SkalliO, GabbianiG. Alpha smooth muscle actin (α-SM actin) in normal human ovaries, in ovarian stromal hyperplasia and in ovarian neoplasms. Virchows Arch B Cell Pathol Incl Mol Pathol, 1989; 57:55.
16.
BeertsenW, EvertsV, van den HooffA. Fine structure of fibroblasts in the periodontal ligament of the rat incisor and their possible role in tooth eruption. Arch Oral Biol, 1974; 19:1087.
17.
BresslerRS. Myoid cells in the capsule of the adrenal gland and in monolayers derived from cultured adrenal capsules. Anat Rec, 1973; 177:525.
18.
YokoiY, NamihisaT, KurodaH, KomatsuI, MiyasakiA, WatanabeS, UsuiK. Immunocytochemical detection of desmin in fat-storing cells (Ito cells)Hepatology, 1984; 4:709.
19.
KapanciY, RibauxC, ChaponnierC, GabbianiG. Cytoskeletal features of alveolar myofibroblasts and pericytes in normal human and rat lung. J Histochem Cytochem, 1992; 40:1955.
20.
CharbordP, LeratH, NewtonI, TamayoE, GownAM, SingerJW, HerveP. The cytoskeleton of stromal cells from human bone marrow cultures resembles that of cultured smooth muscle cells. Exp Hematol, 1990; 18:276.
21.
LindahlP, BetsholtzC. Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B targeted mice. Curr Opin Neprhol Hypertens, 1998; 7:21.
22.
BrownLF, DubinD, LavigneL, LoganB, DvorakHF, Van De WaterL. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol, 1993; 142:793.
23.
DesmouliereA, GabbianiG. The role of the myofibroblast in wound healing, fibrocontrative diseases. The Molecular and Cellular Biology of Wound Repair. ClarkRAF. New York: Plenum Press, 1988; 391–423.
24.
ffrench-ConstantC, Van De WaterL, DvorakHF, HynesRO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol, 1989; 109:903.
25.
SeriniG, Bochaton-PiallatML, RoprazP, GeinozA, BorsiL, ZardiL, GabbianiG. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol, 1998; 142:873.
26.
HinzB, MastrangeloD, IselinCE, ChaponnierC, GabbianiG. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol, 2001; 159:1009.
27.
ZhangK, RekhterMD, GordonD, PhanSH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol, 1994; 145:114.
28.
GabbianiG, HirschelBJ, RyanGB, StatkovPR, MajnoG. Granulation tissue as a contractile organ. A study of structure and function. J Exp Med, 1972; 135:719.
29.
GabbianiG. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol, 2003; 200:500.
TomasekJ, HaaksmaC, SchwartzR, HowardE. Whole animal knockout of smooth muscle alpha-actin does not alter excisional wound healing or the fibroblast-to-myofibroblast transition. Wound Repair Regen, 2013; 21:166.
32.
CoenM, GabbianiG, Bochaton-PiallatML. Myofibroblast-mediated adventitial remodeling: an underestimated player in arterial pathology. Arterioscler Thromb Vasc Biol, 2011; 31:2391.
33.
van den BorneSW, DiezJ, BlankesteijnWM, VerjansJ, HofstraL, NarulaJ. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol, 2010; 7:30.
34.
HinzB, GabbianiG, SeemayerT, SchurchW. Myofibroblast. Histology for Pathologists, 4thMillsSE. Philadelphia, PA: Lippincott, Williams and Wilkins, 2012; 131–178.
35.
HinzB, PhanSH, ThannickalVJ, GalliA, Bochaton-PiallatM-L, GabbianiG. The myofibroblast. Am J Pathol, 2007; 170:1807.
36.
HinzB, PhanSH, ThannickalVJ, PrunottoM, DesmouliereA, VargaJ, De WeverO, MareelM, GabbianiG. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol, 2012; 180:1340.
37.
OlerudJE, OdlandGF, BurgessEM, WyssCR, FisherLD, MatsenFA. A model for the study of wounds in normal elderly adults and patients with peripheral vascular disease or diabetes mellitus. J Surg Res, 1995; 59:349.
38.
BremH, Tomic-CanicM. Cellular and molecular basis of wound healing in diabetes. J Clin Invest, 2007; 117:1219.
39.
MustoeT. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg, 2004; 187:65S.
40.
MustoeT, O'ShaughnessyK, KloetersO. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg, 2006; 117:35S.
41.
AlizadehN, PepperMS, ModarressiA, AlfoK, SchlaudraffK, MontandonD, GabbianiG, Bochaton-PiallatM-L, PittetB. Persistent ischemia impairs myofibroblast development in wound granulation tissue: a new model of delayed wound healing. Wound Repair Regen, 2007; 15:809.
SenCK, RoyS. Oxygenation state as a driver of myofibroblast differentiation and wound contraction: hypoxia impairs wound closure. J Invest Dermatol, 2010; 130:2701.
44.
OrimoA, WeinbergRA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther, 2007; 6:618.
45.
OtrantoM, SarrazyV, BonteF, HinzB, GabbianiG, DesmouliereA. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr, 2012; 6:203.
46.
SugimotoH, MundelTM, KieranMW, KalluriR. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther, 2006; 5:1640.
PaszekMJ, ZahirN, JohnsonKR, LakinsJN, RozenbergGI, GefenA, Reinhart-KingCA, MarguliesSS, DemboM, BoettigerD, HammerDA, WeaverVM. Tensional homeostasis and the malignant phenotype. Cancer Cell, 2005; 8:241.
49.
OrimoA, WeinbergRA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle, 2006; 5:1597.
50.
DvorakHF. Tumors: wounds that do not heal. N Engl J Med, 1986; 315:1650.
51.
SchaferM, WernerS. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol, 2008; 9:628.
52.
HinzB. The myofibroblast paradigm for a mechanically active cell. J Biomechanics, 2010; 43:146.
53.
HinzB. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol, 2007; 127:526.
54.
GabbianiG, RyanGB, MajneG. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 1971; 27:549.
55.
SingerII, KawkaDW, KazazisDM, ClarkRA. In vivo co-distribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface. J Cell Biol, 1984; 98:2091.
56.
SinghP, ReimerCL, PetersJH, SteppMA, HynesRO, Van De WaterL. The spatial and temporal expression patterns of integrin alpha9beta1 and one of its ligands, the EIIIA segment of fibronectin, in cutaneous wound healing. J Invest Dermatol, 2004; 123:1176.
57.
ClarkRAF. Wound repair: overview, general considerations. The Molecular and Cellular Biology of Wound Repair. ClarkRAF. New York: Plenum Press, 1988; 3–50.
58.
BrownLF, YeoKT, BerseB, YeoTK, SengerDR, DvorakHF, Van De WaterL. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med, 1992; 176:1375.
59.
DvorakH. Vascular permeability to plasma, plasma proteins, and cells: an update. Curr Opin Hematol, 2010; 17:225.
60.
YuH, MouwJK, WeaverVM. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol, 2011; 21:47.
61.
GrinnellF, PetrollWM. Cell motility and mechanics in three-dimensional collagen matrices. Annu Rev Cell Dev Biol, 2010; 26:335.
62.
WernerS, GroseR. Regulation of wound healing by growth factors and cytokines. Physiol Rev, 2003; 83:835.
63.
LucasT, WaismanA, RanjanR, RoesJ, KriegT, MullerW, RoersA, EmingSA. Differential roles of macrophages in diverse phases of skin repair. J Immunol, 2010; 184:3964.
64.
VaughanMB, HowardEW, TomasekJJ. Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res, 2000; 257:180.
65.
Chrzanowska-WodnickaM, BurridgeK. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol, 1996; 133:1403.
66.
KlingbergF, HinzB, WhiteES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol, 2013; 229:298.
67.
AroraPD, NaraniN, McCullochCA. The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. Am J Pathol, 1999; 154:871.
68.
AnnesJP. Making sense of latent TGFβ activation. J Cell Sci, 2003; 116:217.
69.
JenkinsG. The role of proteases in transforming growth factor-β activation. Int J Biochem Cell Biol, 2008; 40:1068.
70.
StamenkovicI. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol, 2003; 200:448.
71.
YuQ, StamenkovicI. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev, 2000; 14:163.
72.
SweetwyneM, Murphy-UllrichJ. Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms. Matrix Biol, 2012; 31:178.
73.
FrangogiannisNG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev, 2012; 92:635.
74.
WipffP, HinzB. Integrins and the activation of latent transforming growth factor β1—an intimate relationship. Eur J Cell Biol, 2008; 87:601.
75.
WipffPJ, RifkinDB, MeisterJJ, HinzB. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biol, 2007; 179:1311.
76.
SheppardD. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev, 2005; 24:395.
77.
BershadskyAD, BalabanNQ, GeigerB. Adhesion-dependent cell mechanosensitivity. Annu Rev Cell Dev Biol, 2003; 19:677.
78.
PelhamRJ, WangYl. Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci USA, 1997; 94:13661.
WongVW, RustadKC, AkaishiS, SorkinM, GlotzbachJP, JanuszykM, NelsonER, LeviK, PaternoJ, VialIN, KuangAA, LongakerMT, GurtnerGC. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med, 2011; 18:148.
82.
LiuF, MihJD, SheaBS, KhoAT, SharifAS, TagerAM, TschumperlinDJ. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol, 2010; 190:693–706.
83.
MasurSK, DewalHS, DinhTT, ErenburgI, PetridouS. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci USA, 1996; 93:4219.
84.
DesmouliereA, Rubbia-BrandtL, AbdiuA, WalzT, Macieira-CoelhoA, GabbianiG. a-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by gamma-interferon. Exp Cell Res, 1992; 201:64.
85.
YatesCC, BodnarR, WellsA. Matrix control of scarring. Cell Mol Life Sci, 2011; 68:1871.
86.
MartinP. Wound healing—aiming for perfect skin regeneration. Science, 1997; 276:75.
GuidryC, GrinnellF. Studies on the mechanism of hydrated collagen gel reorganization by human skin fibroblasts. J Cell Sci, 1985; 79:67.
89.
MarenzanaM, Wilson-JonesN, MuderaV, BrownR. The origins and regulation of tissue tension: Identification of collagen tension-fixation process in vitro. Exp Cell Res, 2006; 312:423.
90.
SawhneyRK, HowardJ. Slow local movements of collagen fibers by fibroblasts drive the rapid global self-organization of collagen gels. J Cell Biol, 2002; 157:1083.
WentzelVK. Ornate welts of raised scar tissue are a mark of beauty. National Geographic Societystock picture ID: 615801.
93.
KaramanoukianR, UkatuC, LeeE, HymanJ, SundineM, KobayashiM, EvansGRD. Aesthetic skin branding: a novel form of body art with adverse clinical sequela. J Burn Care Res, 2006; 27:108.
94.
DabiriG, CampanerA, MorganJ, Van De WaterL. A TGF-β1-dependent autocrine loop regulates the structure of focal adhesions in hypertrophic scar fibroblasts. J Invest Dermatol, 2006; 126:963.
95.
DabiriG, TumbarelloDA, TurnerCE, Van De WaterL. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-β1 autocrine loop. J Invest Dermatol, 2008; 128:2518.
96.
DabiriG, TumbarelloDA, TurnderCE, Van De WaterL. TGF-β1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5. J Invest Dermatol, 2008; 128:280.
Kim-KaneyamaJ-R, LeiX-F, AritaS, MiyauchiA, MiyazakiT, MiyazakiA. Hydrogen peroxide-inducible clone 5 (hic-5) as a potential therapeutic target for vascular and other disorders. J Atheroscler Thromb, 2012; 19:601.
99.
MoriK, HamanakaH, OshimaY, ArakiY, IshikawaF, NoseK, ShibanumaM. A HIC-5- and KLF4-dependent mechanism transactivates p21Cip1 in response to anchorage loss. J Biol Chem, 2012; 287:38854.
100.
ShibanumaM, MoriK, NoseK. HIC-5: A mobile molecular scaffold regulating the anchorage dependence of cell growth. Int J Cell Biol, 2012; 2012:1.
101.
LiP, YuX, GeK, MelamedJ, RoederR, WangZ. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol, 2010; 161:1467.
102.
DesmouliereA, RedardM, DarbyI, GabbianiG. Apoptosis medidats the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol, 1995; 146:56.
103.
HeckerL, ThannickalVJ. Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration. Am J Med Sci, 2011; 341:431.
104.
HorowitzJC, LeeDY, WaghrayM, KeshamouniVG, ThomasPE, ZhangH, CuiZ, ThannickalVJ. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem, 2003; 279:1359.
105.
HorowitzJC, RogersDS, SharmaV, VittalR, WhiteES, CuiZ, ThannickalVJ. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal, 2007; 19:761.
106.
ThannickalVJ, HorowitzJC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc, 2006; 3:350.
107.
JunJ, LauL. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol, 2010; 12:676.
108.
JunJ-I, LauLF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov, 2011; 10:945.
109.
KisselevaT, CongM, PaikY, ScholtenD, JiangC, BennerC, IwaisakoK, Moore-MorrisT, ScottB, TsukamotoH, EvansSM, DillmannW, GlassCK, BrennerDA. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA, 2012; 109:9448.
GeigerB, YamadaKM. Molecular architecture and function of matrix adhesions. Cold Spring Harbor Persp Biol, 2011; 3:a005033.
112.
OrrA, HelmkeB, BlackmanB, SchwartzM. Mechanisms of mechanotransduction. Dev Cell, 2006; 10:11.
113.
SchwartzMA. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harbor Perspect Biol, 2010; 2:a005066.
114.
VogelV, SheetzM. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol, 2006; 7:265.
115.
GaoM, CraigD, LequinO, CampbellI, VogelV, SchultenK. Structure and functional significance of mechanically unfolded fibronectin type III1 intermediates. Proc Natl Acad Sci USA, 2003; 100:14784.
116.
ZhongC, Chrzanowska-WodnickaM, BrownJ, ShaubA, BelkinAM, BurridgeK. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J Cell Biol, 1998; 141:539.
117.
SchenkS, QuarantaV. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol, 2003; 13:366.
118.
ArnaoutM, GoodmanS, XiongJ. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol, 2007; 19:495.
119.
CampbellID, HumphriesMJ. Integrin structure, activation, and interactions. Cold Spring Harbor Perspect Biol, 2011; 3:a004994.
120.
LuoB, CarmanC, SpringerT. Structural basis of integrin regulation and signaling. Annu Rev Immunol, 2007; 25:619.
121.
LeaskA. Integrin β1: a mechanosignaling sensor essential for connective tissue deposition by fibroblasts. Adv Wound Care, 2013; 2. 10.1089/wound.2012.0365
122.
MooreSW, Roca-CusachsP, SheetzMP. Stretchy proteins on stretchy substrates: the important elements of integrin-mediated rigidity sensing. Dev Cell, 2010; 19:194.
123.
BalabanNQ, SchwarzUS, RivelineD, GoichbergP, TzurG, SabanayI, MahaluD, SafranS, BershadskyA, AddadiL, GeigerB. Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates. Nat Cell Biol, 2001; 3:466.
RivelineD, ZamirE, BalabanNQ, SchwarzUS, IshizakiT, NarumiyaS, KamZ, GeigerB, BershadskyAD. Focal contacts as mechanosensors: externally applied local mechanical force induces growth of focal contacts by an mDia1-dependent and ROCK-independent mechanism. J Cell Biol, 2001; 153:1175.
126.
del RioA, Perez-JimenezR, LiuR, Roca-CusachsP, FernandezJM, SheetzMP. Stretching single talin rod molecules activates vinculin binding. Science, 2009; 323:638.
127.
JiangG, GiannoneG, CritchleyDR, FukumotoE, SheetzMP. Two-piconewton slip bond between fibronectin and the cytoskeleton depends on talin. Nature, 2003; 424:334.
128.
PapagrigoriouE, GingrasAR, BarsukovIL, BateN, FillinghamIJ, PatelB, FrankR, ZieglerWH, RobertsGC, CritchleyDR, EmsleyJ. Activation of a vinculin-binding site in the talin rod involves rearrangement of a five-helix bundle. EMBO J, 2004; 23:2942.
129.
GrashoffC, HoffmanBD, BrennerMD, ZhouR, ParsonsM, YangMT, McLeanMA, SligarSG, ChenCS, HaT, SchwartzMA. Measuring mechanical tension across vinculin reveals regulation of focal adhesion dynamics. Nature, 2010; 466:263.
130.
CastellaLF, GabbianiG, McCullochCA, HinzB. Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res, 2010; 316:2390.
131.
TomarA, SchlaepferDD. Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr Opin Cell Biol, 2009; 21:676.
132.
MimuraY, IhnH, JinninM, AsanoY, YamaneK, TamakiK. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol, 2005; 124:886.
133.
DeakinNO, TurnerCE. Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. Mol Biol Cell, 2011; 22:327.
134.
DeakinNO, BallestremC, TurnerCE. Paxillin and Hic-5 interaction with vinculin is differentially regulated by Rac1 and RhoA. PLoS One, 2012; 7:e37990.
135.
MianoJM, LongX, FujiwaraK. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol, 2007; 292:C70.
136.
PosernG, TreismanR. Actin’ together: serum response factor, its cofactors and the link to signal transduction. Trends in Cell Biol, 2006; 16:588.
137.
MirallesF, PosernG, ZaromytidouA, TreismanR. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell, 2003; 113:329.
WangX, HuG, BettsC, HarmonEY, KellerRS, Van De WaterL, ZhouJ. Transforming growth factor-β1-induced transcript 1 protein, a novel marker for smooth muscle contractile phenotype, is regulated by serum response factor/myocardin protein. J Biol Chem, 2011; 286:41589.
140.
CriderBJ, RisingerGM, HaaksmaCJ, HowardEW, TomasekJJ. Myocardin-related transcription factors A and B are key regulators of TGF-b1-induced fibroblast to myofibroblast differentiation. J Invest Dermatol, 2011; 131:2378.
141.
WangJ, SuM, FanJ, SethA, McCullochCA. Transcriptional regulation of a contractile gene by mechanical forces applied through integrins in osteoblasts. J Biol Chem, 2002; 277:22889.
142.
HuangX, YangN, FioreVF, BarkerTH, SunY, MorrisSW, DingQ, ThannickalVJ, ZhouY. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol, 2012; 47:340.
143.
McGeeKM, VartiainenMK, KhawPT, TreismanR, BaillyM. Nuclear transport of the serum response factor coactivator MRTF-A is downregulated at tensional homeostasis. EMBO Rep, 2011; 12:963.
144.
SmallEM, ThatcherJE, SutherlandLB, KinoshitaH, GerardRD, RichardsonJA, DiMaioJM, SadekH, KuwaharaK, OlsonEN. Myocardin-related transcription factor-A controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res, 2010; 107:294.
145.
MassziA, SpeightP, CharbonneyE, LodygaM, NakanoH, SzasziK, KapusA. Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. J Cell Biol, 2010; 188:383.
146.
CharbonneyE, SpeightP, MassziA, NakanoH, KapusA. beta-catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial-myofibroblast transition. Mol Biol Cell, 2011; 22:4472.
147.
LevinsonH. A paradigm of fibroblast activation and dermal wound contraction to guide the development of therapies for chronic wounds and pathologic scars. Adv Wound Care, 2013; 2:149.
148.
SharpeJR, MartinY. Strategies demonstrating efficacy in reducing wound contraction in vivo. Adv Wound Care, 2013; 2:167.
149.
WongVW, GurtnerGC. Tissue engineering for the management of chronic wounds: current concepts and future perspectives. Exp Dermatol, 2012; 21:729.
150.
LancerottoL, BayerLR, OrgillDP. Mechanisms of action of microdeformational wound therapy. Semin Cell Dev Biol, 2012; 23:987.
151.
ShirakawaM, IsseroffRR. Topical negative pressure devices: use for enhancement of healing chronic wounds. Arch Dermatol, 2005; 141:1449.
152.
HonardoustD, VarkeyM, HoriK, DingJ, ShankowskyHA, TredgetEE. Small leucine-rich proteoglycans, decorin and fibromodulin, are reduced in postburn hypertrophic scar. Wound Repair Regen, 2011; 19:368.
153.
DanielsonKG, BaribaultH, HolmesDF, GrahamH, KadlerKE, IozzoRV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol, 1997; 136:729.
154.
BaghyK, DezsoK, LaszloV, FullarA, PeterfiaB, PakuS, NagyP, SchaffZ, IozzoRV, KovalszkyI. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest, 2011; 91:439.
155.
NeillT, SchaeferL, IozzoRV. Decorin: a guardian from the matrix. Am J Pathol, 2012; 181:380.
156.
JarvinenTAH. Design of target-seeking antifibrotic compounds. Methods Enzymol, 2012; 509:243.
157.
GrinnellF, ZhuM, CarlsonMA, AbramsJM. Release of mechanical tension triggers apoptosis of human fibroblasts in a model of regressing granulation tissue. Exp Cell Res, 1999; 248:608.
158.
WongVW, BeasleyB, ZepedaJ, DauskardtRH, YockPG, LongakerMT, GurtnerGC. A mechanomodulatory device to minimize incisional scar formation. Adv Wound Care, 2013; 2:185.
159.
ChaponnierC, GoethalsM, JanmeyPA, GabbianiF, GabbianiG, VandekerckhoveJ. The specific NH2-terminal sequence Ac-EEED of a-smooth muscle actin plays a role in polymerization in vitro and in vivo. J Cell Biol, 1995; 130:887.
160.
ClementS, HinzB, DuginaV, GabbianiG, ChapponnierC. The N-terminal Ac-EEED sequence plays a role in -smooth-muscle actin incorporation into stress fibers. J Cell Sci, 2005; 118:1395.
161.
HinzB. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol, 2002; 157:657.
162.
TomasekJ, VaughanM, KroppB, GabbianiG, MartinM, HaaksmaC, HinzB. Contraction of myofibroblasts in granulation tissue is dependent on Rho/Rho kinase/myosin light chain phosphatase activity. Wound Repair Regen, 2006; 14:313.
163.
SatohK, FukumotoY, ShimokawaH. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol, 2011; 301:H287.
164.
Barry-HamiltonV, SpanglerR, MarshallD, McCauleyS, RodriguezHM, OyasuM, MikelsA, VaysbergM, GhermazienH, WaiC, GarciaCA, VelayoAC, JorgensenB, BiermannD, TsaiD, GreenJ, Zaffryar-EilotS, HolzerA, OggS, ThaiD, NeufeldG, Van VlasselaerP, SmithV. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nat Med, 2010; 16:1005.
